Celmatix Clinical Laboratories inside the Commercialization Center for Innovative Technologies — Courtesy: Economic Development Authority
By Joshua Burd
A digital health technology firm is the newest tenant at a state-run incubator in North Brunswick.
The Economic Development Authority said Tuesday that it has welcomed Celmatix Clinical Laboratories to its Commercialization Center for Innovative Technologies. The firm, a subsidiary of Celmatix, has established a new laboratory at the 46,000-square-foot building.
“New Jersey is widely recognized as a leader in innovation,” Melissa Orsen, CEO of the authority, said in a prepared statement. “Combined with CCIT’s array of resources available to emerging life sciences companies, it’s easy to see why Celmatix Founder and CEO Dr. Piraye Yurttas Beim chose to locate Celmatix Clinical Laboratories at our facility.”
Celmatix recently announced Fertilome, the world’s first multigene panel test that reveals how a woman’s DNA may affect her reproductive health, according to a news release. The company was founded to create products that bring greater clarity to the treatment of infertility and pave the way for women to proactively manage their fertility throughout their reproductive life.
The announcement said that, through its products, Celmatix strives to use big data analytics and genomics to help clinics optimize patient outcomes and enhance the patient experience.
“Women struggling with infertility often feel a loss of control over something that is so personal to them, their reproductive health,” Beim said. “Celmatix is committed to empowering women with more personalized information and insights and the work that we plan to do at CCIT will further this mission.”
Its new test is available through physicians and gives women unique genetic insights, allowing them to make more informed, proactive reproductive health decisions. Fertilome “is the result of a multiyear systematic literature review and statistical validation analysis to identify genetic variants that are significantly associated with the most common female reproductive conditions.”
The incubator offers 27 wet labs, the most of any incubator in New Jersey, and is home to nearly two dozen businesses, including both small and large labs and offices. It sits within the Technology Centre of New Jersey, a 75-acre research park that houses such companies as Chromocell and Orthobond, both which once took space at the CCT.
